2021 American Transplant Congress
Elevated Tacrolimus Levels in Hospitalized Organ Transplant Recipients with COVID-19
*Purpose: The effect of COVID-19 on immunosuppressant drug levels in organ transplant recipients (OTRs) has not been adequately studied.*Methods: We retrospectively studied hospitalized adult (>18-year-old)…2021 American Transplant Congress
Impaired Antibody Responses to Spike Protein Antigens of Sars-cov-2 in Solid Organ Transplant (sot) Recipients
*Purpose: Chronic immunosuppression can impair antibody responses after natural infection and vaccination in SOT recipients. It is not known whether antibody responses are impaired in…2021 American Transplant Congress
Monoclonal Antibodies for Covid-19 in Patients with Solid Organ Transplant Recipients
*Purpose: The FDA has issued Emergency Use Authorization (EUA) for monoclonal antibodies for the treatment of mild to moderate COVID-19 in patients at risk for…2021 American Transplant Congress
Disparities in Living Donor Follow-up During the COVID-19 Emergency Suspension of OPTN Follow-up Reporting Requirements
*Purpose: The OPTN temporarily suspended follow-up reporting requirements on 4/3/20 (retroactive to 3/13/20) in response to the COVID-19 crisis. We assessed the policy’s impact on…2021 American Transplant Congress
Covid-19 in Renal Transplant Recipients: Experience of Lithuania
Nephrology, Vilnius University Santaros clinics, Vilnius, Lithuania
*Purpose: Renal transplant recipients are at increased susceptibility to many viral infections, including coronavirus disease 2019 (COVID-19). The purpose of this review is to define…2021 American Transplant Congress
Liver Transplantation for COVID-19-associated Cholangiopathy
*Purpose: The hallmark viral pneumonia of coronavirus-19-disease (COVID-19) is often accompanied by important extra-pulmonary manifestations. Liver dysfunction occurs in up to 45% of COVID-19 patients,…2021 American Transplant Congress
Nurse and Nurse Practitioner-lead Monoclonal Antibody Initiative for Solid Organ Transplant (sot) Recipients with Covid-19
1Johns Hopkins Comprehensive Transplant Center, Baltimore, MD, 2Johns Hopkins, Baltimore, MD
*Purpose: Monoclonal antibody (mAB) infusion (bamlanivimab or casirivimab/imdevimab) for symptomatic, non-hypoxemic, high-risk outpatients with COVID-19 infection, is an available early intervention for COVID-19+ SOT recipients.…2021 American Transplant Congress
Loneliness in Adults Awaiting Liver Transplantation at 7 U.S. Transplant Centers During the Covid-19 Pandemic
*Purpose: Loneliness, defined by the National Academy of Medicine as “a subjective feeling of being isolated”, has recently emerged as a strong predictor of adverse…2021 American Transplant Congress
Bamlanivimab for Covid-19 in Kidney Transplant Patients
Nephrology, Indiana University School of Medicine, Indianapolis, IN
*Purpose: Treatment options for patients with COVID 19 have limited efficacy in reducing severity and duration of viral symptoms as well as progression to severe…2021 American Transplant Congress
SARS-CoV-2 Infection in Solid Organ Transplant Recipients: A Retrospective Cohort Study
Infectious Diseases, University of Massachusetts, Worcester, MA
*Purpose: Initial studies of COVID-19 in solid organ transplant (SOT) recipients demonstrated high mortality rates, but more recent comparative data shows contradictory results.*Methods: We evaluated…
American Transplant Congress abstracts